Ziv-aflibercept

Ziv-aflibercept is a biopharmaceutical drug designed for the treatment of various types of cancer. It operates as an angiogenesis inhibitor, specifically targeting the vascular endothelial growth factor (VEGF) pathway, which is crucial for the process of angiogenesis - the formation of new blood vessels. By inhibiting this pathway, ziv-aflibercept aims to restrict the blood supply to tumors, thereby limiting their growth and potential to spread. This drug is a recombinant fusion protein that combines portions of human VEGF receptors 1 and 2 with the Fc portion of the human IgG1 immunoglobulin.

Mechanism of Action[edit | edit source]

Ziv-aflibercept works by binding to VEGF-A, VEGF-B, and placental growth factor (PlGF) with high affinity. By doing so, it prevents these growth factors from interacting with their natural receptors on the surface of endothelial cells, which are the cells lining the inside of blood vessels. This inhibition blocks the downstream signaling pathways that would normally lead to angiogenesis. As a result, the growth of new blood vessels towards the tumor is halted, effectively starving the tumor of the necessary nutrients and oxygen needed for its growth and survival.

Clinical Uses[edit | edit source]

Ziv-aflibercept is approved for use in combination with a FOLFIRI chemotherapy regimen for the treatment of adults with metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen. The effectiveness of ziv-aflibercept in treating colorectal cancer has been demonstrated in clinical trials, showing an improvement in overall survival and progression-free survival in patients treated with the combination of ziv-aflibercept and FOLFIRI compared to FOLFIRI alone.

Adverse Effects[edit | edit source]

The use of ziv-aflibercept is associated with a range of adverse effects, some of which can be severe. Common side effects include hypertension, proteinuria, fatigue, and gastrointestinal symptoms such as diarrhea and abdominal pain. More serious adverse effects may include hemorrhage, gastrointestinal perforation, and compromised wound healing. Due to these potential risks, careful patient selection and monitoring are essential during treatment with ziv-aflibercept.

Pharmacokinetics[edit | edit source]

Ziv-aflibercept is administered intravenously. Its pharmacokinetic profile is characterized by a biphasic elimination pattern, with a rapid distribution phase followed by a slower elimination phase. The drug's half-life allows for bi-weekly dosing in combination with chemotherapy regimens.

Development and Approval[edit | edit source]

Ziv-aflibercept was developed through a collaboration between Sanofi and Regeneron Pharmaceuticals. It received approval from the United States Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancer in 2012. The approval was based on the results of a pivotal phase III clinical trial that demonstrated the drug's efficacy in extending survival in patients with previously treated metastatic colorectal cancer.

Conclusion[edit | edit source]

Ziv-aflibercept represents a significant advancement in the treatment of metastatic colorectal cancer, offering an additional therapeutic option for patients with this challenging condition. Its development underscores the importance of targeting angiogenesis in cancer therapy and highlights the potential for biologic drugs to improve patient outcomes in oncology.